Myeloid Leukemias: A Glance at Middle Eastern Centers

Figures & data

Figure 1 Geographic area of the study, from El Minya Governorate in the North to Aswan in the south together with Al Wadi Al Jadeed (El Karaga) in the west and Red Sea in the east.

Figure 2 Age groups of the study patients. Group 1 = CML patients (n= 226) and group 2 = AML patients (n = 242).

Table 1 Demographic Characteristics of Myeloid Leukemia Patients at SECI and AUH in the Period from January 2007 to December 2016 (Total Number = 468)

Variable	Group 1 (n=226)	Group 2 (n=242)	Group 2a (n=203)	Group 2b (n=39)	P Value
Demographics Age (years)					0.901
Mean ± SD	43.08±15.25	39.32±14.61	39.37±14.69	39.05±14.38
Range	16–80	17–75	17–75	18–70
Median	43.5	43.0	43.0	40.0
Gender					<0.001*
Male	102 (45.1%)	130 (53.7%)	119 (58.6%)	11 (28.2%)
Female	124 (54.9%)	112 (46.3%)	84 (41.4%)	28 (71.8%)
M/F ratio	0.8	1.2	1.4	0.4
Residence					0.70
Urban	90 (39.8%)	106 (43.8%)	90 (44.3%)	16 (41.0%)
Rural	136 (60.2%)	136 (56.2%)	113 (55.7%)	23 (59.0%)
Occupation					0.11
Housewife	119 (52.7%)	86 (35.5%)	65 (32.0%)	21 (53.8%)
Employed	21 (9.3%)	49 (20.2%)	45 (22.2%)	4 (10.3%)
Farmer	33 (14.6%)	50 (20.7%)	44 (21.6%)	6 (15.4%)
Unemployed	51 (22.6%)	20 (8.3%)	17 (8.4%)	3 (7.7%)
Student	2 (0.9)	37 (15.3%)	32 (15.8%)	5 (12.8)

Notes: Group 1 = CML, group 2 = AML, group 2a = de-novo AML, and group 2b = secondary AML. One-way analysis of variance and the chi-square tests were used for analyses. “*” means statistically significant.

Figure 3 Distribution of the study patients over nine Governorates of Egypt. Group 1 = CML patients (n= 226) and group 2 = AML patients (n = 242).

Figure 4 Pleukemic disorder of group 2 patients.

Abbreviations: CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis.

Figure 5 Distribution of leukemia phases and subtypes among the study patients. The upper panel showed subtypes of group 2 patients and the lower panel is phases of group 1 patients.

Abbreviations: CP, chronic phase; AP, accelerated phase; BT, blastic transformation phase.

Table 2 Treatment Modalities for Myeloid Leukemia Patients at SECI and AUH in the Period January 2007–December 2016 (Total Number = 468)

Type of Treatment		Frequency	Percent
Group 1	Hydroxyurea	119	52.7
	Gleevec	84	37.2
	Others	22	9.7
	Dasatinib	1	0.4
	Total	226	100.0
Group 2	3/7 Induction	139	57.4
	Induction and consolidation	33	13.6
	Others	13	5.4
	Low-dose ara-c	31	12.8
	Vesanoid	26	10.7
	Total	242	100.0

Notes: Group 1 = CML patients, group 2 = AML patients. “Others” for group 1 patients included interferon therapy, treatment of transformation, and for group 2 included supportive treatment, planning for BMT.

Figure 6 Outcome of the study patients. The lower and upper panels showed outcome of groups 1 and 2, respectively.

Abbreviations: DF, disease-free; SCT, stem cell transplantation; SECI, South Egypt Cancer Institute.

Figure 7 Kaplan–Meier survival analysis of group 1 patients.

Table 3 Overall Survival of Group 1 Patients

Patient Sex	Total N	Number of Events	Censored		Mean OS	Log Rank (Mantel-Cox)	P-Value
			N	Percent
Male	102	34	68	66.7	73.339
Female	124	47	77	62.1	60.948	0.057	0.811
Overall	226	81	145	64.2	63.844

Note: Estimation is limited to the largest survival time if it is censored.

Abbreviation: OS, overall survival time.

Figure 8 Kaplan–Meier survival analysis of group 2 patients.

Table 4 Overall Survival of Group 2 Patients

Gender	Total N	Number of Events	Censored		Mean OS	Log Rank (Mantel-Cox)	P-Value
			N	Percent
Male	130	15	115	88.5	29.595
Female	112	22	90	80.4	26.089	1.106	0.293
Overall	242	37	205	84.7	31.494

Note: Estimation is limited to the largest survival time if it is censored.

Abbreviation: OS, overall survival time.